Company intelligence / Profile preview

Carterra

Salt Lake City, Utah, USAcarterra-bio.com ↗

Ownership: Private
Development stage: Other

Overview

Carterra’s high-throughput SPR-based platforms have been widely adopted by leading pharmaceutical companies, CROs, biotechs, and academic centers to accelerate the discovery of novel large and small molecule therapeutics. Their technology was instrumental in the rapid development of bamlanivimab—the first COVID‑19 therapeutic antibody—by Eli Lilly. The company continues to grow rapidly with record revenues as of end of 2024.

Modalities: Monoclonal antibodySmall moleculeProtein (for protein-protein interactions)Molecular glue therapyPROTACsDNA encoded libraries (DELs)
Industry: Drug Discovery Services

Partnerships

Eli LillyStandard BioToolsIPAOrdaōs BiosciencesENPICOMIcosagenVanderbilt University School of Medicine

Beyond the preview

Go deeper on Carterra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carterra.

Explore the full profile